ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- WT1 gene: a potential therapeutic target for multiple cancer treatment strategies.Clinical and experimental medicine · 2025Review
- Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives.Human vaccines & immunotherapeutics · 2024Review
- Harnessing exosomes in theranostic applications: advancements and insights in gastrointestinal cancer research.Discover oncology · 2024Review
- Plasmid DNA for Therapeutic Applications in Cancer.Pharmaceutics · 2022Review
- A Highly Effective System for Predicting MHC-II Epitopes With Immunogenicity.Frontiers in oncology · 2022Article
- Cancer immunotherapy: A comprehensive appraisal of its modes of application.Oncology letters · 2021Review
- Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement.International journal of molecular sciences · 2021Review
- High-throughput 5' UTR engineering for enhanced protein production in non-viral gene therapies.Nature communications · 2021Article
- MMP-7 derived peptides with MHC class-I binding motifs from canine mammary tumor tissue elicit strong antigen-specific T-cell responses in BALB/c mice.Molecular and cellular biochemistry · 2021Article
- Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.Frontiers in immunology · 2021Review
- Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses.Frontiers in immunology · 2020Article
- Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Designing consensus immunogens to break tolerance to self-antigens for cancer therapy.Oncotarget · 2018Article
- Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.Vaccines · 2017Review
- Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.Journal of virology · 2017Article
- Vaccination-induced skin-resident memory CD8OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Tumor-associated antigens have emerged as important immunotherapeutic targets in the fight against cancer. Germline tumor antigens, such as WT1, Wilms' tumor gene 1, are overexpressed in many human malignancies but have low expression in somatic tissues. Recent vaccination approaches to target WT1 have been hampered by poor in vivo immune potency, likely due to the conserved self-antigen nature of WT1. In this study, we use a novel synthetic micro-consensus SynCon DNA vaccine approach with the goal of breaking tolerance and increasing vaccine immune potency. This approach induced new, neo-antigen-like responses that were superior to those induced by native WT1 DNA immunogens for driving T cell immunity and breaking tolerance. Non-human primates (NHPs) vaccinated with SynCon WT1 antigens elicited immune responses against native rhesus WT1 peptides. When delivered by electroporation (EP) in mice, SynCon-based WT1 constructs elicited strong CD4 and CD8 T cell responses (including IFN-γ, CD107a, and TNF-α) to both native and consensus peptides. In addition, SynCon WT1 vaccine-induced antibodies recognized native WT1 in vitro. Vaccination with the SynCon WT1 immunogens was capable of slowing tumor growth in therapeutic models in vivo. These data support the further study of synthetic consensus DNA vaccines for breaking tolerance to important germline antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.